Lilly CEO John Lechleiter was paid $11.2 million in salary, bonus, stock and perks last year, according to Lilly’s proxy statement filed Monday morning. That represented a 10-percent increase over his take in 2012.
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
Zeke Turner, the 36-year-old CEO of Mainstreet Property Group LLC—who frequently sports a boyish grin and a bold-colored dress shirt, but rarely dons a tie—said he’s “just getting started” in transforming the staid nursing home industry.
Scientists have discovered that a gene-regulating protein that protects the developing brain of a fetus resurfaces in old age and may stave off dementia, a finding that could open a new path in Alzheimer’s research.
Obamacare opponents predicted early on that insurance co-ops created by the law would fail, but several are doing well by combining low premiums with a certain homespun appeal.
OnTarget Laboratories LLC’s technology was developed by Philip Low, a Purdue chemistry professor who also created the technology behind Endocyte Inc.
The Lilly-Boehringer drug empagliflozin is projected to reach sales of $295 million for Lilly in 2019, but it won’t be able to sell it until issues are resolved at a German plant.
Hospital company KentuckyOne Health, which employs more than 14,000 people in Kentucky and southern Indiana, says it has laid off about 500 people.
The Indianapolis drugmaker said dulaglutide performed as well as Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk. Analysts think dulaglutide could reach annual sales of $1.5 billion.
Eli Lilly and Co. is buying a privately held, poultry-vaccine maker based in Germany to strengthen its Elanco animal health subsidiary.
Shares of Eli Lilly and Co. rose as much as 3.8 percent Wednesday morning after the Indianapolis-based drugmaker revealed that an experimental drug boosted overall survival among lung cancer patients in a large trial.
Venture capitalists and angel investors put a combined $31.9 million into 18 life sciences companies last year, with some of the largest amounts going to Nextremity Solutions, hc1.com and FAST BioMedical.
U.S. sales are plunging for Roche Diagnostics Corp. and its fellow makers of diabetes-care devices because of lower reimbursements from the federal Medicare program. In five years, two of the four largest companies will have sold or closed their diabetes businesses, according to two industry analysts.
Several million American workers will cut back their hours on the job or leave the nation's workforce entirely because of President Barack Obama's health care overhaul, congressional analysts said Tuesday.
Eli Lilly and Co., Pfizer Inc. and eight other large drugmakers will partner with the U.S. government in a $230 million effort to identify new approaches to treat Alzheimer’s, diabetes, lupus and arthritis.
Testosterone drugs, which make up a growing market for pharmaceutical companies such as Eli Lilly, are getting a closer look from U.S. regulators.
Paris-based Sanofi sued Eli Lilly and Co. on Thursday for patent infringement. That suit triggers an automatic 30-month delay on Lilly’s plans to launch a similar version of Sanofi’s once-a-day insulin Lantus.
Ronald Reed, the owner of Benchmark Mobility Corp., allegedly billed the Medicaid and Medicare programs for used wheelchairs, scooters and lift chairs as if they were brand new, obtaining nearly $443,000 in fraudulent sales.
A newspaper says Eli Lilly and Co. is a leading contender to acquire a Massachusetts-based biotech company with a troubled leukemia drug.
Hill-Rom Holdings Inc. will eliminate about 350 jobs over the next two years as a cost-saving move after the maker of hospital equipment saw its profit grow slower than expected.
